Alzamend Neuro, Inc. reported earnings results for the full year ended April 30, 2023. For the full year, the company reported net loss was USD 14.88 million compared to USD 12.36 million a year ago. Basic loss per share from continuing operations was USD 2.25 compared to USD 2.1 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.7195 USD | +2.79% | +6.51% | -19.16% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-19.16% | 4.94M | |
+1.51% | 42.75B | |
+49.22% | 41.61B | |
+8.57% | 41.34B | |
-12.36% | 26.59B | |
+8.92% | 25.49B | |
-25.13% | 18.12B | |
+29.17% | 12.24B | |
-3.12% | 11.76B | |
+6.35% | 11B |
- Stock Market
- Equities
- ALZN Stock
- News Alzamend Neuro, Inc.
- Alzamend Neuro, Inc. Reports Earnings Results for the Full Year Ended April 30, 2023